Product Images Methylphenidate Hydrochloride

The text describes a figure showing the mean concentration of methylphenidate in the blood of 36 adults after taking a single dose of two different formulations: extended-release tablets (18 mg once daily) and immediate-release tablets (5 mg three times daily, every 4 hours). The graph shows the concentration levels at different time intervals for each formulation.*

The given text provides a figure (Figure 2) that represents the mean scores of the IOWA Conners Inattention/Overactivity Scale for teachers at community schools. The scores are shown for the treatment arms of methylphenidate hydrochloride extended-release tablets (18, 36, or 54 mg, once daily) and placebo. Studies 1 and 2 were 3-way crossover studies with 1 week per treatment arm, while study 3 involved 4 weeks of parallel-group treatments with a Last Observation Carried Forward analysis at week 4. The error bars in the figure represent the mean plus standard error of the mean.*

This is a table showing the recommended starting doses and dose ranges of Methylphenidate Hydrochloride Extended-Release Tablets based on the patient's age. The recommended starting dose for children 6-12 years old is 18 mg per day, with a dose range of 18 mg to 54 mg per day. For adolescents aged 13-17 years old, the recommended starting dose is also 18 mg per day, with a higher dose range of 18 mg to 72 mg per day, not exceeding 2 mg per kg per day. For adults aged 18-85 years old, the recommended starting dose is either 18 mg or 36 mg per day, with a maximum dose range of 18 mg to 72 mg per day.*

This is a table presenting recommended dose conversions from previous methylphenidate regimens to methylphenidate hydrochloride extended-release tablets. It includes the previous methylphenidate daily dose and the corresponding starting dose for the extended-release tablets.*

The table provides information about the exposure of Methylphenidate Hydrochloride Extended-Release Tablets in double-blind and open-label clinical studies on different patient populations including children, adolescents, and adults. The table shows the number of patients (N) and dose range (mg) for each population. For children, the N is 2,216 and the dose range is 18 to 54 mg once daily. For adolescents, the N is 502 and the dose range is 18 to 72 mg once daily. Finally, for adults, the N is 1,188 and the dose range is 18 to 108 mg once daily.*

This is a table showing the adverse reactions reported by children and adolescent subjects who were treated with Methylphenidate hydrochloride extended-release tablets. The table includes four placebo-controlled, double-blind clinical trials of Methylphenidate hydrochloride extended-release tablets. The table displays the system/organ class, adverse reactions, and the percentage of subjects who experienced the reaction after taking the drug. The adverse reactions with a frequency of more than 1% include abdominal pain, vomiting, pyrexia, nasopharyngitis, dizziness, cough, and oropharyngeal pain. The adverse reaction of insomnia includes both initial insomnia and insomnia.*

Table 6 is a report on adverse reactions caused by Methylphonidato Hydrochioride. The data is based on a study conducted on 21% of test subjects who experienced adverse reactions. The study was conducted in two phases and included both placebo and convulsive double-blind methods. The table presents various disorders and their percentage of occurrence in test subjects. These include disorders such as gastrointestinal disorders, headaches, nervousness, and investigations. However, the quality of the text is poor, with multiple typos and missing words, making it difficult to interpret the text accurately.*

Table 6 shows the pharmacokinetic parameters (mean and standard deviation) of Methylphenidate and Methylphenidate hydrochloride extended-release tablets in healthy adults after a single dose of 18mg and 5mg taken thrice daily respectively. The parameters analyzed are Cmax (maximum plasma concentration), Trnax (time to reach maximum plasma concentration), and AUC (area under the plasma concentration-time curve).*

This is a description of a medication called Methylphenidate Hydrochloride USP. It is an extended release tablet that is used under prescription only. Each tablet contains 27 mg of Methylphenidate Hydrochloride USP. It has to be kept out of reach of children and should be stored at 20° to 25°C. It is recommended to dispense it in a tightly closed container with a child-resistant closure. The NDC code is 63629-1902-1.*